Mohammed Imran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammed Imran has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Abul Kalam Najmi
Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
2 shared publications Shadab Samad
Department of Medicine, Maulana Azad Medical College and LNJP Hospital, New Delhi, India
2 shared publicationsAbulKalam Najmi
Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi, India
1 shared publicationAshhar Qadeer
Department of Kulliyat, Faculty of Medicine, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi, India
1 shared publicationMohammad F Rashid
Department of Allied health Sciences, Clinical Research, Jamia Hamdard, New Delhi, India
1 shared publicationMohammad Maaz
Department of Moalijat, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi, India
1 shared publication
Latest Publications
- Open Access
- 1 January 2015
- Published by Medknow in Advanced Biomedical Research
- Vol. 4 (1) , 137
Complementary and alternative medicine iron preparations: A cost-effective, rationale and accessible solution for public health problems
Adv Biomed Res, Official publication of Isfahan University of Medical Sciences,Iran
- 1 January 2015
- Published by Medknow in Advanced Biomedical Research
- Vol. 4 (1) , 137
Open AccessComplementary and alternative medicine iron preparations: A cost-effective, rationale and accessible solution for public health problems
Adv Biomed Res, Official publication of Isfahan University of Medical Sciences,Iran
- Open Access
- 1 January 2014
- Published by Medknow in International Journal of Critical Illness and Injury Science
- Vol. 4 (1) , 3-9
Evaluation of rapid response team implementation in medical emergencies: A gallant evidence based medicine initiative in developing countries for serious adverse events
Background: Rapid response team (RRT) has been implemented in developed countries with the aim of early recognition and response to critical care triggers for the better patient outcome. However, the data concerning their efficacy is hardly available until date from Indian subcontinent. Aims: To evaluate the impact of RRT implementation on patient outcome during medical emergencies. Settings and Design: Retrospective observational study of RRT records of in-bed patients of super specialty academic teaching hospital. Materials and Methods: RRT record forms during the first half of the year from January 2012 to June 2012 were included for all inpatients and out-patients irrespective of their age, gender and diseases profile after their inclusion in the system. Outcomes such as patient stayed in the room, patient transfer to intensive care unit (ICU), patient discharge and generation of code blue event, mortality and length of stay in hospital/ICU were measured. Statistical Analysis: Descriptive analysis was performed with the help of statistical software STATA 9.0 and R 2.13.2 (StataCorp LP, Lakeway Drive College Station, Texas, USA). Results: Analysis of 41 RRT calls showed decreased code blue calls by 2.44% and decrease in mortality by 4.88%. Average length of stay in ICU and hospital post RRT assistance for patients was 2.55 and 6.95 days respectively. Conversely percentage of patients requiring a higher level of care was more (75.61%) than those who stayed in their rooms/wards (24.39%). Conclusion: Implementation of RRT in this hospital was associated with reduced code blue events and its attendant mortality outside the ICU settings. However, more number of patient requiring higher levels of care delineates the need for a larger evidence based medicine study.
- 1 January 2014
- Published by Medknow in International Journal of Critical Illness and Injury Science
- Vol. 4 (1) , 3-9
Open AccessEvaluation of rapid response team implementation in medical emergencies: A gallant evidence based medicine initiative in developing countries for serious adverse events
Background: Rapid response team (RRT) has been implemented in developed countries with the aim of early recognition and response to critical care triggers for the better patient outcome. However, the data concerning their efficacy is hardly available until date from Indian subcontinent. Aims: To evaluate the impact of RRT implementation on patient outcome during medical emergencies. Settings and Design: Retrospective observational study of RRT records of in-bed patients of super specialty academic teaching hospital. Materials and Methods: RRT record forms during the first half of the year from January 2012 to June 2012 were included for all inpatients and out-patients irrespective of their age, gender and diseases profile after their inclusion in the system. Outcomes such as patient stayed in the room, patient transfer to intensive care unit (ICU), patient discharge and generation of code blue event, mortality and length of stay in hospital/ICU were measured. Statistical Analysis: Descriptive analysis was performed with the help of statistical software STATA 9.0 and R 2.13.2 (StataCorp LP, Lakeway Drive College Station, Texas, USA). Results: Analysis of 41 RRT calls showed decreased code blue calls by 2.44% and decrease in mortality by 4.88%. Average length of stay in ICU and hospital post RRT assistance for patients was 2.55 and 6.95 days respectively. Conversely percentage of patients requiring a higher level of care was more (75.61%) than those who stayed in their rooms/wards (24.39%). Conclusion: Implementation of RRT in this hospital was associated with reduced code blue events and its attendant mortality outside the ICU settings. However, more number of patient requiring higher levels of care delineates the need for a larger evidence based medicine study.
- 26 September 2013
- Vol. 10 (3) , 935-40
Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy.
To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-in class novel β3 receptor agonist drug recently approved by the food and drug administration (FDA) for the treatment of overactive bladder (OAB). We conducted a computerized search of the MEDLINE/PUBMED databases with the word Mirabegron, β3 receptor agonist and overactive bladder. Effect of Mirabegron on β3 adrenergic receptor purportedly releases nitric oxide(NO) by an increase in intracellular Ca2+ through accumulation of cyclic adenosine monophosphate (cAMP). Along with NO which relaxes the detrusor muscle, it also releases an urothelial-derived inhibiting factor (UDIF) that inhibits contractions. It increases the bladder capacity by causing bladder relaxation during the storage phase. Mirabegron appears to be a promising treatment in OAB patients by shifting its management from reducing detrusor over-activity to inducing relaxation. Also it lacks the troublesome side effects associated with the standard antimuscarinic management.
- 26 September 2013
- Vol. 10 (3) , 935-40
Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy.
To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-in class novel β3 receptor agonist drug recently approved by the food and drug administration (FDA) for the treatment of overactive bladder (OAB). We conducted a computerized search of the MEDLINE/PUBMED databases with the word Mirabegron, β3 receptor agonist and overactive bladder. Effect of Mirabegron on β3 adrenergic receptor purportedly releases nitric oxide(NO) by an increase in intracellular Ca2+ through accumulation of cyclic adenosine monophosphate (cAMP). Along with NO which relaxes the detrusor muscle, it also releases an urothelial-derived inhibiting factor (UDIF) that inhibits contractions. It increases the bladder capacity by causing bladder relaxation during the storage phase. Mirabegron appears to be a promising treatment in OAB patients by shifting its management from reducing detrusor over-activity to inducing relaxation. Also it lacks the troublesome side effects associated with the standard antimuscarinic management.
- Open Access
- 1 January 2013
- Published by Medknow in Journal of Pharmacy and Bioallied Sciences
- Vol. 5 (1) , 2-9
Clinical research regulation in India-history, development, initiatives, challenges and controversies: Still long way to go
The Central Drugs Standard Control Organisation and its chairman Drug Controller general of India are bequeathed to protect the citizens from the marketing of unsafe medication. The startling findings, of the 59 th report of the Parliamentary Standing Committee on Health and Family Welfare, have uncovered the lax standards followed by the regulatory authorities in India. The growing clinical research after the product patents rights for the pharmaceutical industries as per the trade related aspects of intellectual property rights agreement and adverse drug reaction monitoring of the marketed drugs have raised many ethical and regulatory issues regarding the promotion of new drugs in Indian markets. Many controversial group of medicines; unauthorised and irrational FDCs not relevant to India's medical needs, are available which are not sold in any of the countries with matured regulatory bodies. It becomes vital to understand the history, growth and evolution of the regulatory aspects of drugs which are handled by multiple Ministries and Departments of the Government of India. Although amendment to Schedule Y, registration of Contract Research Organisations, registration of Clinical Trials, Speeding up review process, Pharmacovigilance (PhV) programme for India and Inspection of clinical trial sites have been started by the various regulatory agencies. However due to casual approach in marketing approval for sale of the drugs, the unethical steps taken by some pharmaceutical companies and medical practitioners has reiterated the need to get appropriate understanding of present regulation of drugs and clinical research especially regarding the practical rules and regulations.
- 1 January 2013
- Published by Medknow in Journal of Pharmacy and Bioallied Sciences
- Vol. 5 (1) , 2-9
Open AccessClinical research regulation in India-history, development, initiatives, challenges and controversies: Still long way to go
The Central Drugs Standard Control Organisation and its chairman Drug Controller general of India are bequeathed to protect the citizens from the marketing of unsafe medication. The startling findings, of the 59 th report of the Parliamentary Standing Committee on Health and Family Welfare, have uncovered the lax standards followed by the regulatory authorities in India. The growing clinical research after the product patents rights for the pharmaceutical industries as per the trade related aspects of intellectual property rights agreement and adverse drug reaction monitoring of the marketed drugs have raised many ethical and regulatory issues regarding the promotion of new drugs in Indian markets. Many controversial group of medicines; unauthorised and irrational FDCs not relevant to India's medical needs, are available which are not sold in any of the countries with matured regulatory bodies. It becomes vital to understand the history, growth and evolution of the regulatory aspects of drugs which are handled by multiple Ministries and Departments of the Government of India. Although amendment to Schedule Y, registration of Contract Research Organisations, registration of Clinical Trials, Speeding up review process, Pharmacovigilance (PhV) programme for India and Inspection of clinical trial sites have been started by the various regulatory agencies. However due to casual approach in marketing approval for sale of the drugs, the unethical steps taken by some pharmaceutical companies and medical practitioners has reiterated the need to get appropriate understanding of present regulation of drugs and clinical research especially regarding the practical rules and regulations.
- Open Access
- 1 January 2013
- Published by Medknow in Indian Journal of Transplantation
- Vol. 7 (1) , 28-30
Clinical research on immunosuppressive drugs: The impact of new proposed organ donation guidelines
- 1 January 2013
- Published by Medknow in Indian Journal of Transplantation
- Vol. 7 (1) , 28-30
Open AccessClinical research on immunosuppressive drugs: The impact of new proposed organ donation guidelines
- Open Access
- 1 January 2013
- Published by Medknow in Journal of Mid-life Health
- Vol. 4 (4) , 203-9
Hippocratic oath and conversion of ethico-regulatory aspects onto doctors as a physician, private individual and a clinical investigator
Hippocratic Oath is a living document for ethical conduct of the physicians around the world. World Medical Association has been amending the oath as per the contemporary times. Although physicians maintain their ethical standards while treating a patient yet many a times social, administrative and ruling powers either use physicians as their tool of oppression or victimize them for conducting duties as per their oath. The Tuskegee Syphilis Study and Human Radiation Experiments in America, Nazi Experiments in Germany and compulsory sterilization program in India were the studies where States used physicians for the advancement of their rationality or belief. Conversely victimization of physicians in Kosovo, Sri Lanka and incarcerating physicians for treating human immunodeficiency virus/acquired immunodeficiency syndrome patients in some countries is concerning. The Nuremberg code, the Declaration of Geneva, Belmont Report and Declaration of Helsinki are ethical documents while active involvement of Food and Drug Administration through "common rule" resulted in guidelines like International Conference on Harmonization and Good Clinical Practices. Still unethical studies are found in developing countries. Studies such as experimental anticancer drugs in 24 cancer patients without adequate prior animal testing and informed consent in Kerala, studies at All India Institute of Medical Sciences in New Delhi resulted in 49 deaths of children and many more suspicious studies are rampant. Reverting back to the fundamentals of the medical profession; teaching medical ethics and enforcement of "medical neutrality" by embarking some grade of "medical immunity" on the basis of the oath is necessary for ethical conduct of physicians.
- 1 January 2013
- Published by Medknow in Journal of Mid-life Health
- Vol. 4 (4) , 203-9
Open AccessHippocratic oath and conversion of ethico-regulatory aspects onto doctors as a physician, private individual and a clinical investigator
Hippocratic Oath is a living document for ethical conduct of the physicians around the world. World Medical Association has been amending the oath as per the contemporary times. Although physicians maintain their ethical standards while treating a patient yet many a times social, administrative and ruling powers either use physicians as their tool of oppression or victimize them for conducting duties as per their oath. The Tuskegee Syphilis Study and Human Radiation Experiments in America, Nazi Experiments in Germany and compulsory sterilization program in India were the studies where States used physicians for the advancement of their rationality or belief. Conversely victimization of physicians in Kosovo, Sri Lanka and incarcerating physicians for treating human immunodeficiency virus/acquired immunodeficiency syndrome patients in some countries is concerning. The Nuremberg code, the Declaration of Geneva, Belmont Report and Declaration of Helsinki are ethical documents while active involvement of Food and Drug Administration through "common rule" resulted in guidelines like International Conference on Harmonization and Good Clinical Practices. Still unethical studies are found in developing countries. Studies such as experimental anticancer drugs in 24 cancer patients without adequate prior animal testing and informed consent in Kerala, studies at All India Institute of Medical Sciences in New Delhi resulted in 49 deaths of children and many more suspicious studies are rampant. Reverting back to the fundamentals of the medical profession; teaching medical ethics and enforcement of "medical neutrality" by embarking some grade of "medical immunity" on the basis of the oath is necessary for ethical conduct of physicians.
- Open Access
- 1 January 2013
- Published by Medknow in Perspectives in Clinical Research
- Vol. 4 (2) , 153-4
Discouraging adverse drug reactions reporting culture: Just a tip of the ′Gullible Prescribing′
Perspect Clin Res, Official publication of Indian Society for Clinical Research,India
- 1 January 2013
- Published by Medknow in Perspectives in Clinical Research
- Vol. 4 (2) , 153-4
Open AccessDiscouraging adverse drug reactions reporting culture: Just a tip of the ′Gullible Prescribing′
Perspect Clin Res, Official publication of Indian Society for Clinical Research,India
- Open Access
- 1 January 2012
- Published by Medknow in Perspectives in Clinical Research
- Vol. 3 (4) , 149-50
Pharmacologists′ participation in teaching hospitals for shaping future clinical research in India
Perspect Clin Res, Official publication of Indian Society for Clinical Research,India
- 1 January 2012
- Published by Medknow in Perspectives in Clinical Research
- Vol. 3 (4) , 149-50
Open AccessPharmacologists′ participation in teaching hospitals for shaping future clinical research in India
Perspect Clin Res, Official publication of Indian Society for Clinical Research,India